Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET ...

Zwanger-Pesiri Radiology, one of the most respected and technologically advanced outpatient radiology practices in the Northeast, has implemented Bone Suppression Imaging (BSI) technology from Konica ...

Interested investors and guests of Cocrystal Pharma are welcome to attend the conference at a discounted rate. Please register here using the discount code COCPNOBLECON. A video webcast of the ...

The Tectonic management team will host one-on-one meetings during the two conferences. Interested investors should contact their Piper Sandler and Evercore representatives to schedule meetings.

Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced ...

About Cerevance Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative diseases and obesity. Our proprietary platform, N uclear E nriched T ranscript S ...

Connect, the premier nonprofit organization in San Diego’s innovation ecosystem dedicated to supporting entrepreneurs and cultivating thriving life science and technology communities, announced today ...

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its Board ...

About LockeT Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and ...

Ascentage Pharma will host a Chinese (Mandarin) language investor webcast with Q&A at 9:00 pm EST on December 11, 2025 / 10:00 am HKT December 12, 2025. To access the Chinese language investor event ...

Based on Stoke Therapeutics’ preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific ...

IMP3ACT’s demonstrated capability to create a single antiviral therapeutic against influenza, COVID and RSV has potential to position Salarius to address large existing global commercial opportunity ...